Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ETORICOXIB
Merck Sharp & Dohme Ireland (Human Health) Limited
30 Milligram
Film Coated Tablet
2011-09-16
License Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Acoxxel 30mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 30mg of etoricoxib. Excipient: 30 mg: lactose 1.4 mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet (tablet). 30 mg Tablets: Blue-green, apple-shaped biconvex tablets marked ‘ACX 30’ on one side and ‘101’ on the other. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications For the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4). 4.2 Posology and method of administration Posology As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1). Osteoarthritis Read the complete document